Muromonab-cd3 (Muromonab-cd3)
Overview of Muromonab-cd3
Muromonab-CD3 is a monoclonal antibody (mAb), also known as Orthoclone OKT3 . It is a mouse-derived (murine) monoclonal antibody that specifically binds to the CD3 (T3) protein found on the surface of T cells. It is an intravenous drug, used for the prevention and treatment of transplant rejection.
Indication of Muromonab-cd3
Muromonab-cd3 is primarily indicated in conditions like Graft rejection, Graft versus host disease.
Contraindication of Muromonab-cd3
Muromonab-cd3 is contraindicated in conditions like Hypertension,Fever,Hypersensitivity to the drug.
Side Effects of Muromonab-cd3
The signs and symptoms that are produced after the acute overdosage of Muromonab-cd3 include Hypotension, Pulmonary edema, Convulsions, Seizures, Tachycardia, Hallucinations, Cardiac arrest, Trembling, Bruising.,The symptomatic adverse reactions produced by Muromonab-cd3 are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Diarrhea, Fever, Chills, Tremor, Nausea and vomiting, Faintness, Rigors, GI bleeding, Oedema, dizziness, faintness.
Precautions of Muromonab-cd3
Prescribing should be kept to a minimum in all patients with severe liver disease, especially if jaundice, ascites, or evidence of encephalopathy present. Patient temperature should not exceed 37.8�C (100�F) at time of administration. Severe pulmonary edema has occurred in patients with fluid overload. May result in an increased susceptibility to infection; dosage of concomitant immunosuppressants should be reduced during Muromonab-cd3 therapy; cyclosporine should be decreased to 50% usual maintenance dose and maintenance therapy resumed about 4 days before stopping Muromonab-cd3.